Login
Home
Charts
Search
Watchlist
Products

Inventurus Knowledge Solutions Ltd

IKS·NSE
1,869.20+4.85%Tue, 22 Sept '26

Inventurus Knowledge Solutions Ltd

IKS
NSE
1,869.20
+4.85%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
32,187Cr
Close
Close Price
1,875.00
Industry
Industry
IT Enabled Services/Business Process Outsourcing
PE
Price To Earnings
41.08
PS
Price To Sales
9.62
Revenue
Revenue
3,347Cr
Rev Gr TTM
Revenue Growth TTM
21.10%
PAT Gr TTM
PAT Growth TTM
40.91%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
567620640643657724740781815858894
Growth YoY
Revenue Growth YoY%
15.916.815.621.524.018.520.7
Expenses
ExpensesCr
405494467454476498502509533557599
Operating Profit
Operating ProfitCr
162126173189181226238272282300295
OPM
OPM%
28.620.327.029.427.631.232.134.834.635.033.0
Other Income
Other IncomeCr
61545273323-10
Interest Expense
Interest ExpenseCr
2632262221211816231310
Depreciation
DepreciationCr
1927282828282830323434
PBT
PBTCr
12481122144160180195228229253251
Tax
TaxCr
2217273130324347464757
PAT
PATCr
1026495113130148152181183206194
Growth YoY
PAT Growth YoY%
27.7132.558.759.941.439.427.9
NPM
NPM%
17.910.314.917.619.720.420.523.122.524.021.7
EPS
EPS
6.13.85.86.87.88.99.110.811.012.311.6
QuarterDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
567620640643657724740781815858894
Growth YoY
Revenue Growth YoY%
15.916.815.621.524.018.520.7
Expenses
ExpensesCr
405494467454476498502509533557599
Operating Profit
Operating ProfitCr
162126173189181226238272282300295
OPM
OPM%
28.620.327.029.427.631.232.134.834.635.033.0
Other Income
Other IncomeCr
61545273323-10
Interest Expense
Interest ExpenseCr
2632262221211816231310
Depreciation
DepreciationCr
1927282828282830323434
PBT
PBTCr
12481122144160180195228229253251
Tax
TaxCr
2217273130324347464757
PAT
PATCr
1026495113130148152181183206194
Growth YoY
PAT Growth YoY%
27.7132.558.759.941.439.427.9
NPM
NPM%
17.910.314.917.619.720.420.523.122.524.021.7
EPS
EPS
6.13.85.86.87.88.99.110.811.012.311.6

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5295537641,0311,8182,6643,1943,347
Growth
Revenue Growth%
4.538.235.076.346.519.921.1
Expenses
ExpensesCr
3683494666401,2981,8942,1022,199
Operating Profit
Operating ProfitCr
1612042973915207701,0911,149
OPM
OPM%
30.536.938.937.928.628.934.234.3
Other Income
Other IncomeCr
31161-2403985
Interest Expense
Interest ExpenseCr
776560907062
Depreciation
DepreciationCr
4130232559113124131
PBT
PBTCr
145183269359442606905961
Tax
TaxCr
717365471120183197
PAT
PATCr
137165233305370486722764
Growth
PAT Growth%
20.340.931.021.431.248.540.9
NPM
NPM%
26.029.930.529.620.418.322.622.8
EPS
EPS
171.410.214.318.422.429.243.145.6
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5295537641,0311,8182,6643,1943,347
Growth
Revenue Growth%
4.538.235.076.346.519.921.1
Expenses
ExpensesCr
3683494666401,2981,8942,1022,199
Operating Profit
Operating ProfitCr
1612042973915207701,0911,149
OPM
OPM%
30.536.938.937.928.628.934.234.3
Other Income
Other IncomeCr
31161-2403985
Interest Expense
Interest ExpenseCr
776560907062
Depreciation
DepreciationCr
4130232559113124131
PBT
PBTCr
145183269359442606905961
Tax
TaxCr
717365471120183197
PAT
PATCr
137165233305370486722764
Growth
PAT Growth%
20.340.931.021.431.248.540.9
NPM
NPM%
26.029.930.529.620.418.322.622.8
EPS
EPS
171.410.214.318.422.429.243.145.6

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
881717171717
Reserves
ReservesCr
2744476298121,1401,7732,783
Current Liabilities
Current LiabilitiesCr
815983115790521970
Non Current Liabilities
Non Current LiabilitiesCr
707058451,080741498
Total Liabilities
Total LiabilitiesCr
4345867889883,0283,0524,268
Current Assets
Current AssetsCr
2333454616988987841,310
Non Current Assets
Non Current AssetsCr
2012413272902,1302,2682,958
Total Assets
Total AssetsCr
4345867889883,0283,0524,268
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
881717171717
Reserves
ReservesCr
2744476298121,1401,7732,783
Current Liabilities
Current LiabilitiesCr
815983115790521970
Non Current Liabilities
Non Current LiabilitiesCr
707058451,080741498
Total Liabilities
Total LiabilitiesCr
4345867889883,0283,0524,268
Current Assets
Current AssetsCr
2333454616988987841,310
Non Current Assets
Non Current AssetsCr
2012413272902,1302,2682,958
Total Assets
Total AssetsCr
4345867889883,0283,0524,268

Cash Flow

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
163175233288210318674
Investing Cash Flow
Investing Cash FlowCr
-80-166-82-156-1,141244-210
Financing Cash Flow
Financing Cash FlowCr
-41-37-59-152780-389-412
Net Cash Flow
Net Cash FlowCr
43-2792-20-15117352
Free Cash Flow
Free Cash FlowCr
153168222280183294643
CFO To PAT
CFO To PAT%
118.5105.8100.094.356.665.493.3
CFO To EBITDA
CFO To EBITDA%
101.085.878.473.640.341.361.7
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
163175233288210318674
Investing Cash Flow
Investing Cash FlowCr
-80-166-82-156-1,141244-210
Financing Cash Flow
Financing Cash FlowCr
-41-37-59-152780-389-412
Net Cash Flow
Net Cash FlowCr
43-2792-20-15117352
Free Cash Flow
Free Cash FlowCr
153168222280183294643
CFO To PAT
CFO To PAT%
118.5105.8100.094.356.665.493.3
CFO To EBITDA
CFO To EBITDA%
101.085.878.473.640.341.361.7

Ratios

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
26,16322,79932,187
Price To Earnings
Price To Earnings
53.431.441.1
Price To Sales
Price To Sales
9.87.19.6
Price To Book
Price To Book
14.58.111.5
EV To EBITDA
EV To EBITDA
34.921.227.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
98.997.697.597.193.192.992.492.4
OPM
OPM%
30.536.938.937.928.628.934.234.3
NPM
NPM%
26.029.930.529.620.418.322.622.8
ROCE
ROCE%
53.735.738.641.420.326.327.427.4
ROE
ROE%
48.736.336.036.832.027.225.825.8
ROA
ROA%
31.728.229.630.912.215.916.916.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
26,16322,79932,187
Price To Earnings
Price To Earnings
53.431.441.1
Price To Sales
Price To Sales
9.87.19.6
Price To Book
Price To Book
14.58.111.5
EV To EBITDA
EV To EBITDA
34.921.227.0
Profitability Ratios
Profitability Ratios
GPM
GPM%
98.997.697.597.193.192.992.492.4
OPM
OPM%
30.536.938.937.928.628.934.234.3
NPM
NPM%
26.029.930.529.620.418.322.622.8
ROCE
ROCE%
53.735.738.641.420.326.327.427.4
ROE
ROE%
48.736.336.036.832.027.225.825.8
ROA
ROA%
31.728.229.630.912.215.916.916.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
IKS Health is a care-enablement platform that takes on the administrative, clinical, and financial chores that pull US doctors away from their patients - essentially, it runs the non-clinical side of a physician practice so clinicians can just be clinicians. Founded in 2006, the company spent nearly two decades building a human-led, tech-assisted operating model that has now evolved into an AI-native platform, completing its IPO in India in December 2024. Its recurring approach is to take accountability for outcomes rather than just processing tasks, getting paid as a percentage of its clients’ revenue so that its own success is tied directly to making those practices healthier and more profitable. # Business segments A single integrated platform that delegates every chore across the patient journey - from scheduling to billing to clinical documentation - for over 600 US physician groups and health systems. ## 1. Care Enablement Platform: an operating system for physician enterprises **The platform absorbs the entire administrative and clinical-chore burden of a medical practice, using agentic AI and a global team of clinically trained staff to turn the data in electronic health records into actions, decisions, and revenue.** - **Spans the full patient journey** - the platform covers 16 core workflows across five stages: before the visit (scheduling, financial clearance), during the visit (clinical documentation, scribing), after the visit (coding, billing, payment posting), between visits (prescription renewals, referrals), and inside acute-care settings. - **Three solution pillars under one roof** - Revenue Optimization maximizes collections and minimizes claim denials; Clinical Support streamlines documentation, coding, and transcription; and Value-Based Care helps practices succeed in outcome-based payment models by coordinating care and managing risk. - **AI that knows when to act and when to ask** - the platform’s automation runs on a five-level scale from fully manual to fully autonomous, with the company tracking autonomy feature by feature based on whether the outcome is deterministic or not, and whether the task touches an outside entity that may not be technology-ready. - **A suite of proprietary engines** - the platform includes Optimix for revenue-cycle orchestration, IKS EVE™ for autonomous patient access and scheduling, Q CODE for AI-driven coding, the Scribble Suite™ for ambient clinical documentation, AssuRx™ for prescription renewals, and Stacks™ for document management, all fed by a Unifying Data Platform that aggregates data from billing systems, EHRs, and clearinghouses. - **Glass-box AI as a trust layer** - the company’s AI maps documentation to standardized medical ontologies, validates relationships against known medical knowledge, and flags ambiguity when confidence is low, routing the case to a human reviewer so that every prediction is transparent, explainable, and auditable. # Revenue model and commercial approach **IKS gets paid as a percentage of its clients’ revenue - not by the headcount or transaction - so when its AI and workflows make a task more efficient, the client saves money and IKS captures the efficiency in its own margins.** - **Outcome-based pricing, not FTE-based** - unlike traditional IT services or BPO firms that bill per person deployed, IKS links its revenue to demonstrable client outcomes, which is why it does not disclose conventional contract-value metrics like ACV or TCV. - **Two pools of economic value** - the model gives IKS both a recurring revenue stream as a percentage of client revenue and a direct share in the EBITDA improvement its platform generates, with some deals structured under a Net Economic Value Added (NEVA) model where IKS earns a portion of the uplift it creates. - **Non-linear growth** - revenue grows significantly faster than headcount because the platform automates more work over time; in the most recent quarter, revenue grew 5.2% sequentially while net headcount actually declined. - **Sticky by design** - 90% of revenue comes from repeat customers, client retention exceeds 99%, and the top 10 clients have an average relationship of nearly six years, because the platform becomes deeply embedded in the practice’s daily operations. # Group structure and partners **The listed Indian parent sits atop a US operating subsidiary that runs the platform, with a series of acquisitions - AQuity, ThinkDTM, Arai Solutions, and the pending TruBridge deal - adding inpatient capabilities, AI talent, and a proprietary electronic health record for the rural hospital market.** - **Parent and principal operating subsidiary** - Inventurus Knowledge Solutions Ltd is listed on the BSE and NSE; its wholly owned US subsidiary, IKS Inc., incorporated in Delaware in 2006, is the entity that delivers the care-enablement platform to American healthcare providers. - **AQuity brought inpatient scale** - the $200 million acquisition in FY25 added clinical documentation, coding, and medico-legal solutions for the inpatient market, along with 500-plus enterprise customers; the acquired operating model was subsequently transformed from a heavy US-based human-led model to a tech-led, offshore-enabled one, expanding margins. - **ThinkDTM and Arai deepen the AI stack** - the acqui-hire of ThinkDTM in March 2026 brought in the team that built the MyCare Hub agentic-AI patient-engagement platform, while the May 2026 acquisition of Arai Solutions added proprietary neuro-symbolic models, knowledge graphs, and ontologies that reduce dependency on third-party AI infrastructure and accelerate the build of small language models. - **TruBridge adds a system of record for rural hospitals** - the pending $565 million acquisition of NASDAQ-listed TruBridge would bring a proprietary EHR installed in 700 to 800 rural and community hospitals, covering over 15 million patients, creating a closed-loop combination of IKS’s System of Action with a System of Record and opening a $575 million-plus whitespace for the platform inside TruBridge’s client base.

Documents — Inventurus Knowledge Solutions Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/pf489my0ft8teqt7x0tqiu5c.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/vcom5n7lmubkepbk5u4z3dgo.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/7ibxxbzd9wtga8cch7fb1gll.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/rw4tm5ud7qmkyi03cckn8c0s.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/c62ezy2e6zsabr53f78zbcig.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/yduxj12yf3ulzr1dblkgeuvh.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/ed45d5f8v4lpxzprgz7scksk.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/blsac2sscg6k5hg2d69ajbc0.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/e38cmtz8hvsnff50gn4tite7.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/x0in23900lqplihnbw82cabt.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/v8ar9efw93vdf2h2zfwb2btn.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/e5wfn9um8sccn0gt38xfq23f.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/yvk2fbz4cynupxrqdos6dyo3.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/ocigcw1a9tjpdzogf8je11d3.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/ah0x4mayo7cric7fpkvvg9zj.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/k3ay8cubkgs04uqr8dqe7muq.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/l398qubkxqxuf7ylbhunqhlo.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/pr0il8ahp68ao1q4fp64h849.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/w3e0225xl2ry5xheeeq2z27j.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/1xpeo5nkwlnsqhndik9pu4rz.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/91iw3xbenv1en9t4lddkdatu.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/duknabrg995fsgeqiuujxdqd.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/bw7bn97p85vpxfm1w29bbscu.pdf

Concall Transcript Summaries — Inventurus Knowledge Solutions Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202606/pf489my0ft8teqt7x0tqiu5c.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202603/vcom5n7lmubkepbk5u4z3dgo.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202512/7ibxxbzd9wtga8cch7fb1gll.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202509/rw4tm5ud7qmkyi03cckn8c0s.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202506/c62ezy2e6zsabr53f78zbcig.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202503/yduxj12yf3ulzr1dblkgeuvh.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AIKS/transcript-notes/202412/ed45d5f8v4lpxzprgz7scksk.pdf